Resistance to paclitaxel mediated by P-glycoprotein can be modulated by changes in the schedule of administration

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 3, 1997, Pages 245-250

  Zhan, Zhirong ^a   Scala, Stefania ^a   Monks, Anne ^b   Hose, Curtis ^b   Bates, Susan ^a   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Drug resistance; P glycoprotein; Paclitaxel; Resistance reversal; Scheduledependence

Indexed keywords

CYCLOSPORIN; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; GLYCOPROTEIN P; PACLITAXEL; VERAPAMIL; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER CELL; CROSS RESISTANCE; CYTOTOXICITY; DRUG ADMINISTRATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARCINOMA; CELL DEATH; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; TUMOR CELLS, CULTURED;

EID: 0030922506     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050654     Document Type: Article

References (33)

1. Akiyama S, Shiraishi N, Kuratomi Y, Nakagawa M, Kuwano M (1986) Circumvention of multiple-drug resistance in human cancer cells by thioridazine, trifluoperazine and chlorpromazine. J Natl Cancer Inst 76: 839-844
2. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T (1995) Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 95: 2205-2214
3. De Brabander M, Geuens G, Nuydens R, Willebrodes R, DeMey J (1981) Taxol induces the assembly of free microtubules in living cells and blocks the organizing capacity of the centrosomes and kinetochores. Proc Natl Acad Sci USA 78: 5608-5612
4. Einzig AL (1994) Review of phase II trials of Taxol (paclitaxel) in patients with advanced ovarian cancer. Ann Oncol 5 [Suppl 6]: S29-32
5. Eisenhauer E, Bokkel-Huinink WW ten, Swenerton KD, Gianni L, Myles J, Burg ME van der, Kerr I, Vermorken JB, Buser K (1993) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose vs low-dose and long vs short infusion. J Clin Oncol 12: 2654-2666
6. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171
7. Holmes FA, Walters RS, Theriault RI, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN (1991) Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805
8. Hsu SI, Lothstein I, Horwitz SB (1989) Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes. J Cell Biochem 264: 12053-12062
9. Jordan M, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556
10. Juliano RL, Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162
11. Kumar N (1981) Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256: 10435-10441
12. Lai G-M, Chen Y-N, Mickley LA, Fojo AT, Bates SE (1991) P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 49: 696-703
13. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1993) Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68: 1104-1109
14. Liebmann J, Cook JA, Lipschultz C, Teague D, Fisher J, Mitchell JB (1994) The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol 33: 331-339
15. Lothstein L, Hsu SI, Horwitz SB, Greenberger LM (1990) Alternate overexpression of two P-glycoprotein genes is associated with changes in multidrug resistance in a J7742 cell line. J Biol Chem 265: 1821-1831
16. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273-279
17. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Camphell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766
18. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA (1993) Paclitaxel plus recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943 1951
19. Roy SN, Horwitz SB (1985) A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res 45: 3856-3863
20. Sarosy G, Kohn E, Stone DA, Rothenberg M, Jacob J, Adamo DO, Ognibene FP, Cunnion RE, Reed E (1992) Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10: 1165-1170
21. Schilf PB, Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565
22. Schilf PB, Horwitz SB (1981) Taxol assembles tubulin in the absence of exogenous guanosine 5′ triphosphate or microtubule-associated proteins. Biochem 20: 3247 3252
23. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 22: 665-667
24. Seidman AD, Norton L, Reichman BS, Crown JP, Yao TJ, Hakes TB, Lebwohl DE, Gilewski TA, Hudis CA, Surbone A (1993) Preliminary experience with paclitaxel (TAXOL) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer. Semin Oncol 4: 40-45
25. Seidman AD, Hochhauser D, Gollub M, Edelmun B, Yao TJ, Hudis CA, Francis P, Fennelly D, Gilewski TA, Moynahan ME, Currie V, Baselga J, Tong W, O'Donaghue M, Salvaggio R, Auguste L, Spriggs D, Norton L (1996) Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase H pharmacokinetic and pharmacodynamic study in metastatic cancer. J Clin Oncol 14: 1877 1884
26. Sikic BI (1993) Modulation of multidrug resistance: at the threshold. J Clin Oncol 11: 1629-1635
27. Thigpen T, Vance R, Puneky L, Khansur T (1994) Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 55 (3 part 2): S97-107
28. Van der Blick AM, Borst P (1989) Multidrug resistance. Adv Cancer Res 52: 165-203
29. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93: 2325-2327
30. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D (1993) Measurement of Cremophor EL following Taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 85: 1685-1690
31. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo AT, Steinberg SM, Goldspiel BR, Herdt J, O'Shaughnessy J, Balis FM, Chabner BA (1994) Paclitaxel (Taxol) in doxorubicin or mitoxantrone refractory breast cancer. J Clin Oncol 12: 1621 1629
32. Wilson WH, Chabner BA, Bryant G, Bates SE, Fojo AT, Regis J, Jaffe ES, Steinberg S, Goldspiel BR, Cheson BD, Wittes RE (1995) A phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 13: 381-386
33. Younes A, Ayoub JP, Hagemeister FB, Mclaughlin P, Sarris A, Rodriguez MA, Swan FJr, Romaguera JE, Martin J, Cabanillas F (1996) No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol 14: 543-548